Setting and study population
vaginal bleeding, gynaecological cancer, metabolic diseases, venous thromboembolism, hypersensitivity, diabetes
VAGINAL BLEEDING, COAGULATION DISORDERS, HEPATIC DISORDER, RECRUITMENT, METABOLIC DISEASES, HYPERTENSION, HYPERSENSITIVITY, DIABETES
Between August 15th, 2016 and September 30th, 2019, we conducted a randomized prospective open-label study of women aged 18 to 42 years who were interested in using ENG-IMPLANT and were willing to have 90 days of pre-treatment with DSG. The study was conducted in the family planning clinic of the Geneva University Hospitals and women’s policlinic of the University Hospital Basel. The exclusion criteria were pregnancy, lactation, vaginal bleeding of unknown origin, wish to become pregnant, weight > 80 kg, history of venous thromboembolism, hypertension, diabetes or other metabolic diseases, coagulation disorders, severe hepatic disorder, history of gynaecological cancer, known hypersensitivity to study drugs and current treatment with enzyme inducing drugs. The study was approved by the ethics committees of both hospitals (CCER 16-972). All patients signed an informed consent prior to recruitment.